Stock comparison
Halozyme Therapeutics
The Pennant Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
PNTG
The Pennant Group
Market cap
$1.19B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | PNTG | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 59C | HALO |
| Benjamin Graham | 73B | 76B | PNTG |
| Philip Fisher | 55C | 59C | PNTG |
| Peter Lynch | 43D | 50C | PNTG |
| Joel Greenblatt | 30F | 43D | PNTG |
| Charlie Munger | 70B | 38D | HALO |
| Terry Smith | 74B | 35D | HALO |
Side-by-side metrics
| Metric | HALO | PNTG |
|---|---|---|
| Market cap | $8.41B | $1.19B |
| P/E (TTM) | 24.0x | 39.1x |
| EV/EBIT | 10.2x | 31.7x |
| ROIC (TTM) | 23.65% | 4.96% |
| Gross margin | 81.24% | 14.78% |
| Net margin | 23.13% | 2.96% |
| Revenue CAGR 5y | 33.23% | 21.17% |
| EPS CAGR 5y | -1.98% | 83.65% |
| Debt / Equity | 1.0x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Net margin23.13%vs 2.96%+87%
- Market cap$8.41Bvs $1.19B+86%
- Gross margin81.24%vs 14.78%+82%
- ROIC (TTM)23.65%vs 4.96%+79%
PNTG leads on
- EPS CAGR 5y83.65%vs -1.98%+102%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.